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ABSTRACT
Recent studies show that talin2 has a higher affinity to β-integrin tails and is 
indispensable for traction force generation and cell invasion. However, its roles in 
cell migration, cancer cell metastasis and tumorigenesis remain to be determined. 
Here, we used MDA-MB-231 human breast cancer cells as a model to define the roles 
of talin2 in cell migration, invasion, metastasis and tumorigenesis. We show here 
that talin2 knockdown (KD) inhibited cell migration and focal adhesion dynamics, 
a key step in cell migration, and that talin2 knockout (KO) inhibited cell invasion 
and traction force generation, the latter is crucial for cell invasion. Re-expression of 
talin2WT in talin2-KO cells restored traction force generation and cell invasion, but that 
of talin2S339C, a β-integrin-binding deficient mutant, did not. Moreover, talin2 KO (or 
KD) suppressed tumorigenesis and metastasis in mouse xenograft models. However, 
surprisingly, re-expression of talin2WT in talin2-KO cells did not rescue tumorigenesis. 
Thus, talin2 is required for breast cancer cell migration, invasion, metastasis and 
tumorigenesis, although exogenous expression of high levels of talin2 could inhibit 
tumorigenesis.
INTRODUCTION
Integrin-mediated mechanic signals regulate tumor 
cell migration, invasion, growth and metastasis [1–6]. 
Integrins are heterodimers, comprising of α (alpha) and β 
(beta) subunits [7]. Talin, a large focal adhesion protein, 
binds to the β subunits, thus activating integrin and 
regulating a variety of physiological and pathological 
processes [8–11]. 
There are two talin genes, Tln1 and Tln2, encoding 
talin1 and talin2, respectively [12]. Talin1 is essential for 
cell migration, invasion, tumor growth and metastasis 
[13–16]. Talin1 regulates focal adhesion (FA) dynamics 
[13, 17, 18] and invadopodium formation [19], key 
steps in cell migration and invasion [20–22]. Talin1 
also mediates calpain-induced FA disassembly [17, 
18]. Along with our collaborators, we have shown that 
talin1 phosphorylation by Cdk5 regulates FA dynamics, 
integrin activation, cell migration and invasion [13, 14]. 
It recruits the moesin-NHE1 complex to modulate pH 
at invadopodia, consequently governing invadopodium 
stability and matrix degradation [19]. It is also required 
for the generation of mechanical force [23], a driver of 
cell migration and invasion. However, the role of talin2 in 
these processes are less understood. It has been reported 
that depletion of talin2 does not influence β1-integrin 
activation [14], and that talin2-ablated mice are viable 
[24]. Thus, it was originally thought that talin2 functioned 
redundantly with talin1. 
However, we demonstrated that talin2 had a stronger 
binding to β integrin tails than talin1 [25, 26]. Talin2 
Ser339 is largely responsible for this affinity difference 
and substitution of Ser339 with Leu disrupted the binding 
of talin2 to β1-integrin tails. We also demonstrated 
that talin2 is localized at invadopodia and that a strong 
talin2-integrins interaction is required for traction force 
generation and invadopodium formation and cell invasion 
[25].
In the present study, we used highly aggressive 
breast cancer cell line MDA-MB-231 cells as a model to 
investigate the role of talin2 in cell migration, invasion, 
tumor growth and metastasis. We found that talin2 plays a 
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crucial role in cell migration, invasion, tumorigenesis and 
metastasis, although exogenous expression of high levels 
of talin2 could suppress tumorigenesis. 
RESULTS
To examine the role of talin2 in cell migration, 
endogenous talin2 in MDA-MB-231 cells were depleted 
by expressing talin2 shRNA (Figure 1A). Cell migration 
was determined by time-lapse cell migration assays, 
as described previously [27]. Depletion of talin2 
significantly suppressed the migration of MDA-MB-231 
cells (Figure 1B), by inhibiting directionality and velocity 
(Figure 1C). Depletion of talin1 also inhibited cell 
migration. However, talin1 affected velocity more than 
directionality, whereas talin2 functioned oppositely (Data 
not shown). To further examine the biological function 
of talin2, we used CRISPR/Cas9 to knockout talin2 from 
MDA-MB-231 cells. Ablation of talin2 was achieved 
by infecting the cells with lentiviruses that express 
Cas9 and talin2 gRNAs. Talin2 was completely ablated 
in clones #1, #3 and #4, while was partially in clone #2 
(Figure 2A). Thus, we chose clones #1, #3, and #4 for 
further experiments. We examined the role of talin2 in cell 
migration using transwell migration assays. Ablation of 
talin2 significantly inhibited cell migration in the absence 
of a growth factor chemoattractant, whereas had no 
effect on EGF-induced cell migration (20 ng/ml EGF in 
lower chambers; Supplementary Figure 1). These results 
suggest that talin2 has distinct roles in cell migration under 
different conditions.
Because FA dynamics is crucial for cell migration, 
we examined the role of talin2 in FA dynamics. MDA-
MB-231 cells that stably express DsRed-paxillin were 
infected with lentiviruses that express talin2 shRNA. 
FA assembly and disassembly were determined as we 
described previously [13, 27]. As shown in Figure 1D 
and 1E, depletion of talin2 significantly inhibited both 
FA assembly/disassembly rates in MDA-MB-231 
cells, suggesting that talin2 regulates cell migration by 
modulating FA dynamics. 
To ascertain the role of talin2 in breast cancer cell 
invasion, the invasion of talin2 knockout (KO) cells was 
measured by examining the functional capacities of the 
cells penetrating through transwell filters coated with 
0.35 mg/ml Matrigel, using cells infected with empty 
LentiCrispr vector as a control. Ablation of endogenous 
talin2 significantly inhibited the basal (without growth 
factors) as well as HGF-stimulated invasion of MDA-
MB-231 cells (Figure 2B, 2C). Depletion of talin2 by using 
shRNAs also inhibited the invasion of MDA-MB-468 and 
MDA-MB-435S cells (Supplementary Figure 2). 
Previously, we demonstrated that substitution of 
S339 with Cys caused significant reduction in the binding 
of the talin2 head domain to β-integrin tails [25]. We 
examined whether the mutation also inhibits the binding 
of the full-length talin2 to β-integrins. As shown in 
Figure 2D, substitution of S339 with Cys also resulted in 
significant reduction in the binding of the full-length talin2 
to β1A-integrin tail.
To determine the essential role of the talin2-β-
integrin interaction in cell invasion, EGFP-talin2WT and 
-talin2S339C were re-expressed in talin2-null MDA-MB-231 
cells, respectively (Figure 2E). The invasive capacities of 
these cells toward Matrigel were tested, using talin2-null 
cells and CRISPR vector cells as controls. Expression of 
EGFP-talin2WT in talin2-null cells significantly rescued the 
basal and HGF-stimulated cell invasion (Figure 2F, 2G). 
Expression of EGFP-talin2S339C had no effect on basal 
invasion, but partially rescued HGF-stimulated invasion 
(P < 0.05 KO vs S339C), suggesting that a strong binding 
of talin2 to integrins is required for cell invasion. 
Because traction force plays an important role in 
cell migration and invasion [23, 25, 28], we set out to 
examine the role of talin2 in traction force generation. 
To this end, talin2-null MDA-MB-231 cells were 
plated on the fibronectin-conjugated polyacrylamide 
gels containing Red Fluospheres (Life Technologies), 
using cells carrying empty CRISPR vector as a control. 
Traction force was measured by a Nikon A1 confocal 
microscope equipped with a CO2 incubator system, and 
was analyzed using the method of Butler et al. Ablation 
of talin2 almost abolished the traction force generation in 
MDA-MB-231 cells (Figure 3A, 3B). To know whether a 
strong talin2-β-integrin interaction is required for traction 
force generation, talin2-null MDA-MB-231 cells that 
express EGFP-talin2WT or –talin2S339C were plated on the 
gels containing Red FluoSpheres, and traction force was 
measured using talin2-null cells and CRISPR vector cells 
as controls. Expression of EGFP-talin2WT in talin2-null 
MDA-MB-231 cells restored more than 85% of traction 
force, whereas that of EGFP-talin2S339C, which has reduced 
affinity to β-integrins, had little effect (Figure 3C, 3D). 
This result suggests that a strong binding of talin2 to 
β-integrins is required for traction force generation. 
To study the role of talin2 in tumorigenesis, talin2-
null MDA-MB-231 cells were injected into female 
NCRNU mice (Taconic) by subcutaneous injection, using 
cells that were infected with empty LentiCrispr vector 
as a control. Tumor volumes were measured at 3–7 day 
intervals. As shown in Figure 4A, tumor volumes from 
mice injected with talin2-null cells were significantly 
smaller than those from mice injected with the cells 
transfected with empty vector. At 36 days after injection, 
mice were euthanized, and tumors were removed, 
photographed and weighted. Talin2 KO significantly 
inhibited tumor growth (Figure 4B, 4C). The role of 
talin2 in tumorigenesis was further demonstrated by 
using talin2 KD cells. To compare the roles of talin1 and 
talin2 in tumorigenesis, talin1 and talin2 were depleted 
with talin1 and talin2 shRNAs, respectively (Figure 4D). 
MDA-MB-231 cells that express talin2 shRNAs were 
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injected into female NCRNU mice by subcutaneous 
injection, using cells expressing talin1 shRNA and cells 
transfected with empty pLKO.1 vector as controls. Tumor 
volumes were measured at 3 day intervals. As shown 
in Figure 4E, tumor volumes from mice injected with 
the cells expressing talin2 shRNA were significantly 
smaller than those injected with the cells transfected 
with empty vector, and were similar to those injected 
with the cells expressing talin1 shRNA. At 30 days 
after injection, mice were euthanized, and tumors were 
removed, photographed and weighted. Either talin1 or 
talin2 knockdown (KD) significantly inhibited tumor 
growth (Figure 4F, 4G). Depletion of talin1 or talin2 also 
suppressed cell proliferation in vitro (Figure 4H). These 
data suggest that, like talin1, talin2 is also indispensable 
for breast cancer cell tumorigenesis. 
To determine whether a strong talin2-β-integrin 
interaction is essential for tumorigenesis, talin2-null 
MDA-MB-231 cells that re-express EGFP-talin2WT 
or –talin2S339L were injected into female NCRNU mice 
(Taconic) by subcutaneous injection, using talin2 null 
cells as a control. Surprisingly, re-expression of talin2WT 
in talin2-null cells completely abolished tumor growth, 
whereas re-expression of talin2S339L, an integrin-binding 
Figure 1: Talin2 is essential for cell migration and FA dynamics in MDA-MB-231 cells. (A) MDA-MB-231 cells were 
infected with lentiviruses that express talin2 shRNAs or empty pLKO.1 vector (shRNA control). (B) Migration tracks of 10 MDA-MB-231 
cells that stably express talin2 shRNAs or empty pLKO.1 vector. (C) Statistic results of velocity, total path length, net distance, and 
directionality of the cells that stably express shRNA control or talin2 shRNA. The data are expressed as mean + S.E.M. of more than 50 
cells from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to control cells. (D) MDA-MB-231 cells that stably 
express mDsRed-paxillin were infected with lentiviruses that express talin2 shRNA or empty pLKO.1 vector. The cells were plated on 
fibronectin and the dynamics of paxillin were analysed using time-lapse TIRF microscopy. Inserts show enlarged FAs. Scale bar, 20 μm. 
(E) Quantification of the FA assembly and disassembly rate constants in MDA-MB-231 cells that express talin2 shRNAs or empty pLKO.1 
vector. Quantifications are expressed as mean ± S.E.M. of 60 FAs from 12 cells.
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deficient mutant, partially inhibited tumor growth (Figure 
5B–5D). This inhibition is probably caused by the high 
levels of re-expressed talin2WT, which are three fold higher 
than the endogenous talin2 (Figure 5A). These results 
suggest that exogenous expression of high levels of talin2 
can inhibit tumorigenesis more efficiently than talin2 KD 
(or KO).
To know the role of talin2 in breast cancer cell 
metastasis, MDA-MB-231 cells that express talin2 
shRNA or a control shRNA were injected into the tail 
vein of female NCRNU mice (Taconic), comparing to 
cells expressing talin1 shRNA. After six weeks, mice 
were euthanized and tumor nodules on the surface of the 
lungs were examined microscopically. The lungs from 
the mice injected with the cells expressing talin1 or talin2 
shRNAs had significantly less tumor nodules than those 
injected with the cells infected with the control shRNA 
(Figure 6A). Also, hematoxylin and eosin staining showed 
that the lung sections from the mice injected with cells 
expressing the control shRNA demonstrated numerous 
tumor nodules, whereas those from mice injected with 
cells expressing talin1 or talin2 shRNAs had fewer or no 
tumor nodules (Figure 6B). These results indicate that both 
talin1 and talin2 are indispensable for the metastasis of 
MDA-MB-231 cells. 
To examine the possible association of talin2 with 
breast cancer progression, human breast cancer tissue 
array slides, including 17 cases of ductal carcinoma in situ 
(DCIS), 32 cases of invasive ductal carcinoma (IDC) and 
30 cases of tumor adjacent tissues, were stained for talin2. 
Figure 2: Strong binding of talin2 to integrins is required for the invasion of MDA-MB-231 cells. (A) Endogenous talin1 
and talin2 in CRISPR vector-transfected and talin2-KO MDA-MB-231 cells. (B) Ablation of talin2 inhibited the invasion of MDA-MB-231 
cells. HGF (20 ng/ml) was added to lower chambers where indicated. (C) Quantification of Experiment “B”. Data are presented as mean 
± SEM from three independent experiments. t-test, *P < 0.05, **P < 0.01, compared to CRISPR control. (D) Binding of full-length EGFP-
talin2WT or –talin2S339C to β1A-integrin tails measured by GST pull-down assays. The EGFP fusion proteins of talin mutants were transiently 
expressed in CHO-K1 cells. (E) Stable expression of EGFP-talin2WT and -talin2S339C in talin2-null MDA-MB-231 cells using CRISPR. (F) 
Talin2-null MDA-MB-231 cells that express EGFP-talin2WT or –talin2S339C were examined for their Matrigel invasive capacities, using 
CRISPR vector-infected cells and talin2-null cells as controls. (G) Quantification of Experiment “E”. Data are presented as mean ± SEM 
from three independent experiments. t-test, *P < 0.05 and ***P < 0.001, compared to CRISPR control.
Oncotarget106880www.impactjournals.com/oncotarget
Immunohistochemical staining was performed as we 
described previously [29]. Talin2 staining was significantly 
higher in DCIS and IDC tissues than the staining in the 
adjacent tissues (P < 0.001), and talin2 staining was 
also higher in IDC tissues than DCIS tissues (P < 0.001; 
Figure 6C). These data suggest that talin2 expression 
positively correlates with human breast cancer progression.
DISCUSSION
In breast cancer cells, talin2 mediates traction 
force generation through its high affinity to β-integrins, 
thus regulating cell migration, invasion, tumor growth 
and metastasis. Talin2 is indispensable for tumor growth, 
although exogenous expression of excessive talin2 can 
inhibit tumor growth.
We found that depletion of talin2 inhibited the 
directionality of cell migration in time-lapse migration 
assays, and that ablation of talin2 suppressed cell migration 
in transwell migration assays in the absence of a growth 
factor as a chemoattractant (Figure 1, Supplementary 
Figure 1). Although the time-lapse migration assays were 
performed in the presence of EGF, there was no EGF 
gradient in the assays. Thus, the common factor in these 
two different assays is lack of EGF gradient, suggesting 
that talin2 is indispensable for cell migration when there is 
no signal cue for the directionality. In contrast, talin2 KO 
had no significant effect on cell migration in the presence 
of EGF in transwell assays, where the EGF gradient 
determined the directionality of migration. This result is 
consistent with previous findings that talin2 deleted mouse 
embryo fibroblasts showed no obvious defects in the 
velocity of migration [24]. These results suggest that talin2 
regulates cell migration by governing the directionality.
The role of talin2 in determining the directionality 
of cell migration could be attributed to its effect in traction 
Figure 3: Strong binding of talin2 to β-integrin tails is required for traction force generation. (A) Effects of talin2 KO 
on traction force generation in MDA-MB-231 cells. Scale bar, 30 μm. (B) Quantitative constrained traction force in talin2-ablated MDA-
MB-231 cells, using cells carrying CRISPR vector as a control. Data are presented as mean ± SEM of at least 20 cells from each group. 
t-test, *P < 0.05 and **P < 0.01, compared to CRISPR control. (C) Re-expression of talin2WT in talin2-null MDA-MB-231 cells restored 
their traction force generation, but that of talin2S339C did not. Talin2-null MDA-MB-231 cells that express EGFP-talin2WT or –talin2S339C 
were cultured on polyacrylamide gel containing Red FluoSpheres for determining traction force, using CRISPR vector-infected cells and 
talin2-null cells as controls. Scale bar, 30 μm. (D) Quantitative constrained traction force. Data are presented as mean ± SEM of at least 40 
cells from each group. t-test, ***P < 0.001, compared to talin2 KO cells.
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force (Figure 3), which can regulate the directionality of 
cell migration [30]. Traction force also regulates focal 
adhesion dynamics [31–34], a key step in cell migration 
[20]. This is supported by our findings that talin2 is 
required for focal adhesion dynamics (Figure 1D, 1E). 
Moreover, focal adhesions are implicated in determining 
the directionality of cell migration [35, 36]. Thus, talin2 
regulates the directionality of migration by modulating 
traction force and focal adhesion generation. 
We recently reported that talin2 is required for EGF-
stimulated invasion of U2 OS human osteosarcoma cells 
[25]. We show here that ablation of talin2 also inhibited 
Figure 4: Talin2 is indispensable for tumor growth in a xenograft model of human breast cancer. (A–C), Talin2 KO 
suppressed breast cancer tumorigenesis. Talin2 KO MDA-MB-231 cells (1 × 106) were injected subcutaneously to female NCR-NU mice 
(five to six weeks old), using CRISPR vector cells as a control. Tumor size was measured when indicated with calipers, and tumor volumes 
were calculated and plotted (A). After 36 days, mice were euthanized. Tumors were removed, fixed and photographed (B). Tumor weights 
were measured with a balance with 0.001 g readability (C). (D) MDA-MB-231 cells were infected with lentiviruses that express talin1 or 
talin2 shRNAs, using empty pLKO.1 vector as a control. (E–G) Both talin1 and talin2 KD inhibited tumor growth. Talin1 or talin2 KD 
MDA-MB-231 cells (1 × 106) were injected to female NCR-NU mice (five to six weeks old), using pLKO.1 vector cells as a control. Tumor 
volumes were calculated and plotted (E). After 30 days, mice were euthanized. Tumors were removed, fixed and photographed (F). Tumor 
weights were measured (G). (H) Growth curves of talin1 and talin2 KD cells, compared to pLKO.1 vector cells.
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the invasion of MDA-MB-231 cells and traction force 
generation (Figures 2, 3). Furthermore, re-expression 
of talin2WT in talin2-null MDA-MB-231 cells rescued 
cell invasion and traction force generation, whereas re-
expression of talin2S339C, a β-integrin-binding deficient 
mutant, did not. These results indicate that a strong 
interaction between talin2 and β-integrins is essential 
for traction force generation and cell invasion. Because 
traction force plays an important role in invadopodia [25], 
a key cellular structure for invasion, we conclude that 
talin2-mediated traction force regulates breast cancer cell 
invasion. 
Talin1 knockdown in MDA-MB-231 cells inhibited 
their tumorigenesis (Figure 4). This is consistent with 
a previous report in human hepatocellular carcinoma 
cells [16]. Similar to talin1, talin2 is also indispensable 
for tumorigenesis in MDA-MB-231 cells. Ablation of 
talin2 in MDA-MB-231 cells by CRISPR inhibited their 
tumorigenesis (Figure 4). Similar result was observed in 
mice injected with talin2 knockdown MDA-MB-231 cells. 
These results suggest that talin2 is essential for tumor 
growth. 
Surprisingly, re-expression of talin2WT in talin2-null 
MDA-MB-231 cells did not rescue their tumorigenesis; 
instead, it completely abolished tumor growth (Figure 5). 
The inhibition of talin2 is probably associated with the 
abnormal expression levels of the exogenous talin2, 
which is much higher than the endogenous. The inhibition 
is dependent of the interaction of talin2 with β-integrins, 
because re-expression of talin2S339L, a β–integrin-binding 
deficient mutant, only partially inhibited tumor growth. 
Thus, raising talin2 expression could be a better strategy 
to inhibit breast cancer cell tumorigenesis than depleting 
it, and it is likely that an activator (but not an inhibitor) of 
the talin2-β-integrin interaction should be developed for 
cancer treatment. 
Nevertheless, the inhibition of talin2 on 
tumorigenesis seems to be inconsistent with our 
findings that talin2 staining in DCIS and IDC tissues 
was significantly higher than the staining in the 
adjacent tissues (Figure 6). The reason could be that the 
exogenously expressed talin2 is much higher than the 
talin2 expression in DCIS and IDC. Because a gene has to 
collaborate with many other genes in the gene regulatory 
network to regulate breast cancer growth [37, 38], it is 
likely that exogenous over-expression of talin2 alone will 
disrupt the gene regulatory network. Thus, to exogenously 
express talin2 or its mutants in breast cancer cells for 
studying tumor growth, a weaker promoter (such as EF-
1α) should be selected.
Figure 5: Re-expression of talin2 in talin2-null MDA-MB-231 cells abolished their tumorigenesis. (A) Stable expression 
of EGFP-talin2WT and -talin2S339L in talin2-null MDA-MB-231 cells using CRISPR. B-D, Talin2-KO MDA-MB-231 cells that re-express 
EGFP-talin2WT or -talin2S339L were injected subcutaneously to female NCR-NU mice, using talin2-KO cells as a control. Tumor size was 
measured when indicated, and tumor volumes were calculated and plotted (B). After 39 days, mice were euthanized. Tumors were removed, 
and photographed (C). Tumor weights were measured (D).
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MATERIALS AND METHODS
Reagents
Anti-talin1 (clone 97H6) and anti-talin2 (clone 
53.8) antibodies were from AbD Serotec. Anti-talin2 
rabbit polyclonal antibody (PB9961) was from Boster 
(Pleasanton, CA). Anti-tubulin (C-terminus) mouse 
monoclonal antibody (TP1691) was from ECM 
Biosciences (Versailles, KY). Anti-GAPDH goat 
polyclonal antibody (A00191) was from Genescript 
(Piscataway, NJ). pLKO1 lentivirus shRNAs that 
respectively target talin1 and talin2 were from Sigma. 
Talin1 shRNA clones are TRCN0000123105 (#1), 
TRCN0000299020 (#2) and TRCN0000299022 (#3). 
Talin2 shRNA clones are TRCN0000122990 (#1) 
and TRCN0000122992 (#2). LentiCRISPRv2 and 
pSpCas9(BB)-2A-Puro V2.0, which were generated by 
Dr. Feng Zhang’s Laboratory [39], were from Addgene. 
Alexa488-labeled gelatin and Red FluoSpheres were from 
Life Technologies. Dylight 680 labeled goat anti-rabbit 
IgG (H+L) and Dylight 800-labeled goat anti-mouse 
IgG (H+L) were from Thermo Scientific. Fibronectin 
were from Akron Biotech. Growth factor- reduced 
Matrigel was from BD Bioscience. Pfu Ultra was from 
Agilent Technologies. Cold Fusion Cloning Kit was 
from System Biosciences (Palo Alto, CA). Anti-GFP 
monoclonal antibody and Safectine RU50 transfection kit 
were purchased from Syd Labs (Malden, MA). Standard 
VECTASTAIN ABC kit and ImmPACT DAB substrate kit 
were from Vector Laboratories, Inc. DNA primers were 
synthesized by Sigma-Aldrich.
Plasmid construction
The full-length pEGFP-talin2WT, pEGFP-talin2S339C, 
pAAVS1-EGFP-talin2WT and pAAVS1-EGFP-talin2S339C 
were reported previously [25]. The full-length pEGFP-
talin2S339L was created by digesting full-length pEGFP-
talin2 with BsrG1/EcoRV and ligating the resulting larger 
fragment with the smaller fragment from pEGFP-talin21-
449
S339L. The full-length pAAVS1-EGFP-talin2S339L was 
created by digesting full-length pAAVS1-EGFP-talin2WT 
with BsrG1/EcoRV and ligating the resulting larger 
fragment with the smaller fragment from pEGFP-talin21-
449
S339L. All plasmids were sequenced by Eurofins MWG 
Operon (Huntsville, AL).
Cell culture and transfection 
CHO-K1 Chinese hamster ovary cells, MDA-
MB-231 human breast cancer cells, and 293T human 
embryonic kidney cells were from the American Type 
Culture Collection and were maintained in DMEM 
medium (Corning Inc.) containing 10% fetal bovine serum 
(FBS), penicillin (100 U/ml) and streptomycin (100 µg/
Figure 6: The roles of talin1 and talin2 in the metastasis of MDA-MB-231 cells. (A) MDA-MB-231 cells that express shRNA 
control, talin1 shRNA or talin2 shRNA were injected into the tail veins of ICR-SCID mice. After six weeks, lungs were excised, and the 
numbers of tumor nodules on the lung surface were examined under a dissection microscope and plotted. *P < 0.05. (B) Hematoxylin and 
eosin staining (40×) of paraffin-embedded sections of lung specimens from nude mice implanted with MDA-MB-231 cells that express 
shRNA control, talin1 shRNA or talin2 shRNA. (C) Talin2 staining of human ductal carcinoma in situ and invasive ductal carcinoma tissues 
as well as tumor adjacent tissue.
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ml). CHO-K1 and 293T cells were transfected with 
Safectine RU50 according to the manufacturer’s protocol. 
shRNA knockdown
shRNA plasmids were co-transfected with 
packaging plasmids (pMDLg/pRRE, pRSV-Rev, and 
CMV-VSVG) into 293T cells using Safectine RU50 
transfection reagent according to the manufacturer’s 
protocol. The virus particles were applied to overnight 
cultures of breast cancer cells for infection. Cells that 
stably express shRNAs were obtained by selecting the 
infected cells with 1 μg/ml puromycin for 10 days. 
Talin2 re-expression by CRISPR 
Talin2-null MDA-MB-231 cells were reported 
previously [25]. To re-express of talin2 and talin2S339L in 
talin2-null MDA-MB-231 cells, AAVS1 gRNA was co-
transfected with pAAVS1-EGFP-talin2WT and -EGFP-
talin2S339L into talin2 null cells. Transfected cells were 
selected with neomycin. EGFP-positive clones were 
isolated. The re-expression of EGFP-talin2WT and -EGFP-
talin2S339L was examined by western blot.
Cell migration assays
Cells were treated with trypsin and resuspended 
in DMEM medium containing 1% FBS and 10 ng/ml 
EGF, plated at low densities on glass-bottomed dishes 
(MatTek) coated with 5 µg/ml fibronectin and cultured 
for three hours in a CO2 incubator. Cell motility was 
measured with a Nikon Biostation IMQ. Cell migration 
was tracked for six hours; images were recorded every 10 
minutes. The movement of individual cell was analyzed 
with NIS-Elements AR (Nikon) as described previously 
[27, 29]. 
To perform Transwell migration assays, Transwell 
polycarbonate filters were coated with fibronectin (20 µg/
ml) for one hour. Cells were trypsinized and washed 3 
times with DMEM containing 1% FBS. The cells were 
resuspended in DMEM containing 1% FBS at a density 
of 5 × 105 cells/ml. The cell suspensions (100 µl) were 
seeded into the upper chambers, and 600 µl of DMEM 
medium containing 1% FBS, and 10 µg/ml fibronectin 
(and 20 ng/ml EGF where indicated) were added to the 
lower chambers. The cells were allowed to migrate for 3.5 
hours (or as indicated) in a CO2 incubator, fixed, stained 
and quantitated as described previously [40].
FA dynamics assays
MDA-MB-231 cells that stably express DsRed-
paxillin [27] were infected with lentiviruses that express 
shRNA control, talin1 or talin2 shRNA and then selected 
with puromycin. The cells were trypsinized and plated 
on MatTek dishes (with a glass coverslip at the bottom) 
that had been precoated with fibronectin (5 µg/ml). The 
cells were cultured for three hours and TIRF images 
were taken using the Nikon Eclipse Ti TIRF microscope 
equipped with a 60×, 1.45 NA objective, CoolSNAP HQ2 
CCD camera (Roper Scientific). The temperature, CO2 
and humidity were maintained by using INU-TIZ-F1 
microscope incubation system (Tokai Hit). Images were 
recorded at 1-minute intervals for a 60-minute period. FA 
assembly and disassembly rate constants were analyzed as 
described previously [13, 27, 40]. 
Cell invasion assays 
Cell invasion was performed as described previously 
[29, 40]. Briefly, 100 µl of Matrigel (1:30 dilution in 
serum-free DMEM medium) was added to each Transwell 
polycarbonate filter and incubated at 37°C for five 
hours. Cells were trypsinized, washed (three times), and 
resuspended in DMEM containing 1% FBS at a density 
of 5 × 105 cells/ml. The cell suspensions (100 µl) were 
seeded into the upper chambers, and 600 µl of DMEM 
medium containing 1% FBS, 20 ng/ml HGF and 10 µg/ml 
fibronectin were added to the lower chambers. The cells 
were allowed to invade for 10 hours (or as indicated) in a 
CO2 incubator, fixed, stained and quantitated as described 
previously [40].
Traction force measurement
Traction force was measured as described previously 
[23, 25]. Briefly, glass-bottom dishes were silanized using 
silane, and activated using glutaraldehyde. Forty µL of 
gel containing acrylamide (6%), bis-acrylamide (0.75%), 
ammonium persulfate, TEMED, and FluoSpheres® 
carboxylate-modified beads (diameter 0.2 μm, 1:85 
dilution by volume) was added to the dishes and covered 
by a coverslip. The coverslip was removed, and gels 
were activated with sulfo-SANPAH under UVA exposure 
and then conjugated with fibronectin (0.1 mg/ml). Cells 
were plated on the gels and traction force was measured 
as described previously [41], using an A1 confocal 
microscope in Lexington VA Medical Center.
Tumor growth assays
Female NCR-NU mice (Taconic, six–seven weeks 
old) were maintained and treated under pathogen-free 
conditions. MDA-MB-231 cells (1 × 106 cells/mouse) 
were injected subcutaneously to female NCR-NU mice. 
The injected mice were maintained under standard humane 
conditions. Tumor volume (V) was measured with calipers 
periodically and calculated by using formula V = 0.5 × 
LW2 (L, Length; and W, width). Mice were euthanized 
after 30–40 days. Tumors were removed, weighed and 
photographed. 
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Tumor metastasis assays
Tumor metastasis was performed as described 
previously [27]. Briefly, female ICR-SCID mice 
(Taconic) were maintained and treated under pathogen-
free conditions. Talin1 or talin2 KD MDA-MB-231 cells 
(1 × 106 cells/mouse) were injected into the tail vein of 
mice (six–seven weeks old), using shRNA vector cells as 
a control. After six weeks, mice were euthanized and lungs 
were removed and photographed. Tumor nodules present 
on the surface of lungs were examined under a dissection 
microscope or detected in paraffin-embedded sections 
stained with hematoxylin and eosin. 
Immunohistochemical staining
Breast cancer tissue arrays, with stage, grade and 
normal breast tissue, were purchased from US BioMax. 
The slides with tissue arrays were deparaffinized with 
Xylene, dehydrated through three alcohol changes, and 
performed antigen retrieval in 0.1 M citrate buffer (pH 
6.0). The slides were treated with hydrogen peroxide 
and then blocked with goat serum. The slides were 
incubated with an affinity purified anti-talin2 rabbit 
polyclonal antibody and then VECTASTAIN ABC kit 
(Vector Laboratories, Inc). The slides were visualized 
by incubating with a DAB substrate kit from the same 
company. The correlation between talin2 expression and 
tumor progression was scored and statistically analyzed.
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